Who Loses More Weight on a GLP-1?

“Will it work for someone like me?” is the question underneath most of what people read about these drugs. A systematic review pooled 64 randomized trials to answer it, and found essentially one difference: women lost more than men. Age, race, ethnicity, starting BMI and starting blood sugar made no measurable difference at all.^[1]

What differed, and what did not

Across six trials covering 19,906 patients analyzed by sex, weight loss was 10.9% among women (95% CI 7.0 to 14.8) against 6.8% among men (95% CI 4.6 to 9.0).^[1]

Why the empty column is the useful one

Most coverage of these drugs is built on the assumption that response varies enormously and that the trick is finding your personal angle. This review suggests the opposite: the drug behaves about the same across the characteristics people most often worry about.

Starting heavier did not change the percentage lost. Neither did being older, or your race, or your blood sugar.

⚠ One caveat arrived after this was written: a large real-world cohort DID find outcomes differing by race and ethnicity, which we take apart in who responds in the real world. The short version is that trials equalize cost, supply and dose escalation, and ordinary care does not — so the gap is in the conditions rather than in the patients. That is worth knowing before you pay for a program built around personalization, and it sits alongside a different finding worth holding at the same time: group averages never predict an individual. Consistency across subgroups is not the same as consistency between people. Individual variation within every one of those groups remains large.

How much weight the nulls can carry

Less than the headline implies, and the review is transparent about it. Look at the middle column of that table again: the HbA1c conclusion rests on four trials and 1,886 patients. That is a weak basis for “no difference”, and it is not the same as evidence that no difference exists.

• Absence of a detected difference is not proof of sameness, especially in the smaller analyses.
• Subgroup analysis is exploratory by nature even when pre-specified, because trials are powered for their main outcome and not for slices of it.
• Reporting was uneven. Baseline BMI was examined in 75% of the trials, sex in only 21% — so the subgroups that matter most to individual readers are the least studied.

About the sex difference specifically

It is real in this analysis and it is easy to over-interpret. Percentage weight loss is not a pure measure of drug response — women on average carry a higher proportion of body fat, so the same absolute loss registers as a larger percentage. Differences in starting weight, in body composition and in dosing relative to body size all feed into that gap.

So the honest version is that women lost a larger share of their body weight in these trials, and that the reasons are not established. It is not a finding that the drug works better in women in any mechanistic sense, and nobody should choose or avoid treatment on the basis of it.